|
Market Closed -
Nasdaq
00:00:00 16/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 28.93 USD | +3.93% |
|
-1.26% | +6.52% |
| 09-22 | Top Midday Decliners | MT |
| 09-22 | Celldex Therapeutics, Inc. - Special Call |
Company Valuation: Celldex Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,803 | 2,099 | 2,169 | 1,677 | 1,805 | 2,272 | - | - |
| Change | - | 16.42% | 3.32% | -22.7% | 7.65% | 25.88% | - | - |
| Enterprise Value (EV) 1 | 1,395 | 1,794 | 1,745 | 951.2 | 1,286 | 1,610 | 1,638 | 1,674 |
| Change | - | 28.64% | -2.73% | -45.5% | 35.21% | 25.14% | 1.79% | 2.16% |
| P/E | -23.6x | -18.6x | -13.6x | -10.3x | -6.96x | -6.89x | -6.78x | -8.55x |
| PBR | - | - | - | 2.25x | 3.43x | 3.83x | 3.76x | 4.16x |
| PEG | - | -0.4x | -0.6x | 0.6x | -0.1x | -0.91x | -4x | 0.4x |
| Capitalization / Revenue | 388x | 891x | 315x | 239x | 1,168x | 1,228x | 228x | 17.9x |
| EV / Revenue | 300x | 761x | 254x | 136x | 832x | 870x | 165x | 13.2x |
| EV / EBITDA | - | - | -11.3x | -4.96x | -4.53x | -4.96x | -4.73x | -7.07x |
| EV / EBIT | -19.6x | -15.6x | -12.3x | -4.88x | -4.48x | -4.77x | -4.42x | -5.46x |
| EV / FCF | -22.4x | -17x | -16x | -5.96x | -6.02x | -5.85x | -5.91x | -11x |
| FCF Yield | -4.46% | -5.88% | -6.25% | -16.8% | -16.6% | -17.1% | -16.9% | -9.11% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.64 | -2.4 | -2.92 | -2.45 | -3.9 | -4.196 | -4.267 | -3.383 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.651 | 2.357 | 6.883 | 7.02 | 1.545 | 1.85 | 9.954 | 126.7 |
| EBITDA 1 | - | - | -154.5 | -191.9 | -284 | -324.3 | -346.6 | -236.7 |
| EBIT 1 | -71.24 | -115.2 | -142 | -195.1 | -287.4 | -337.6 | -370.5 | -306.4 |
| Net income 1 | -70.51 | -112.3 | -141.4 | -157.9 | -258.8 | -319.2 | -360.9 | -315.9 |
| Net Debt 1 | -408.2 | -305 | -423.6 | -725.3 | -518.6 | -662.3 | -633.5 | -598.1 |
| Reference price 2 | 38.64 | 44.57 | 39.66 | 25.27 | 27.16 | 28.93 | 28.93 | 28.93 |
| Nbr of stocks (in thousands) | 46,664 | 47,100 | 54,689 | 66,344 | 66,449 | 78,530 | - | - |
| Announcement Date | 28/02/22 | 28/02/23 | 26/02/24 | 27/02/25 | 25/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.89x | 870.06x | -4.96x | -.--% | 2.27B | |
| 20.07x | 7.14x | 14.31x | 1.48% | 68.98B | |
| 28.61x | 7.85x | 24.63x | 0.05% | 53.15B | |
| 35.29x | 6.26x | 18.73x | 0.92% | 50.83B | |
| 34.21x | 3.36x | 14.49x | -.--% | 44.61B | |
| -19.62x | 197.94x | -20.83x | -.--% | 40.57B | |
| 49.56x | 5.68x | 31.19x | -.--% | 42.53B | |
| 27.19x | 7.72x | 19.99x | 0.39% | 30.95B | |
| 29.37x | 6.23x | 16.17x | -.--% | 25.44B | |
| -13.66x | 5.14x | -6.23x | -.--% | 22.66B | |
| Average | 18.41x | 111.74x | 10.75x | 0.28% | 38.2B | |
| Weighted average by Cap. | 23.04x | 31.78x | 13.75x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CLDX Stock
- Valuation Celldex Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
